Clinical Impact of Post-Progression Survival on Overall Survival in Elderly Patients with Non-Small-Cell Lung Cancer Harboring Sensitive < b > < i > EGFR < /i > < /b > Mutations Treated with First-Line EGFR Tyrosine Kinase Inhibitors
Conclusions: PPS has a stronger impact on OS than PFS does in elderly patients with NSCLC harboring sensitiveEGFR mutations and treated with first-line EGFR-TKI. These results indicate that OS in this patient population may be influenced by treatments subsequent to first-line chemotherapy; however, this remains to be verified in prospective studies.Chemotherapy 2018;63:181 –189 (Source: Chemotherapy)
Source: Chemotherapy - August 14, 2018 Category: Cancer & Oncology Source Type: research

Host Directed Therapies for Tuberculosis: Futures Strategies for an Ancient Disease
The emergence and spread of drug-resistant strains ofMycobacterium tuberculosis is worsening the global threat of tuberculosis (TB). There is a need and urgency for the development of new treatments for TB, for the management of drug resistant TB (MDR-TB) and for improved regimens against drug-susceptible TB, with the goal of reducing toxicity and length of therapy that will boost patience compliance. The paucity of new drugs is a major obstacle to design new regimens while host-directed therapies (HDTs) are emerging as a promising area of research and are opening new avenues to fight TB. In this review, we discuss example...
Source: Chemotherapy - July 20, 2018 Category: Cancer & Oncology Source Type: research

Specifications of Computerized Provider Order Entry and Clinical Decision Support Systems for Cancer Patients Undergoing Chemotherapy: A Systematic Review
Conclusion: In complicated settings such as chemotherapy, simplification of the processes is more imperative. The use of chemotherapy CPOE, which includes specifications for helping the medical staff with their workload, encourages the professionals to use such systems and increases the likelihood for success of these systems.Chemotherapy 2018;63:162 –171 (Source: Chemotherapy)
Source: Chemotherapy - July 3, 2018 Category: Cancer & Oncology Source Type: research

Isoliquiritigenin Suppresses Osteosarcoma U2OS Cell Proliferation and Invasion by Regulating the PI3K/Akt Signalling Pathway
Conclusion: ISL could retard proliferation and promote apoptosis of U2OS cells possibly by suppressing the PI3K/Akt signalling pathway, indicating that it might be a potential therapeutic agent for osteosarcoma treatment.Chemotherapy 2018;63:155 –161 (Source: Chemotherapy)
Source: Chemotherapy - June 22, 2018 Category: Cancer & Oncology Source Type: research

Genetic Diversity of < b > < i > Mycobacterium tuberculosis < /i > < /b > Isolates in the Metropolitan Area of Rome
Conclusions: Dynamics of TB transmission in Rome indicate recent spread ofMtb strains belonging to phylogeographic lineages and clades usually found in countries and geographic areas with a high incidence of TB, similarly to what is observed in most metropolitan areas in Western Europe. Knowledge from molecular and classical epidemiology provides an important tool for disease control.Chemotherapy 2018;63:148 –154 (Source: Chemotherapy)
Source: Chemotherapy - June 14, 2018 Category: Cancer & Oncology Source Type: research

Current Opinion and Knowledge on Peritoneal Carcinomatosis: A Survey among a Swiss Oncology Network
Conclusion: Usefulness of and satisfaction with available treatment options for PM were rated as moderate at best by oncological experts, and treatment strategies differed importantly among participants. There appears to be a clear need for standardization and new treatment modalities.Chemotherapy 2018;63:143 –147 (Source: Chemotherapy)
Source: Chemotherapy - June 13, 2018 Category: Cancer & Oncology Source Type: research

Carboplatin Dosing Accuracy by Estimation of Glomerular Filtration versus Creatinuria in Cancer Patients
Conclusions: GFR formulae and calculation of the carboplatin dose have good accuracy with the GFR obtained based on the 24-h creatinine clearance, with the Wright formula being the one with best performance and CG the one with worst performance.Chemotherapy 2018;63:137 –142 (Source: Chemotherapy)
Source: Chemotherapy - May 16, 2018 Category: Cancer & Oncology Source Type: research

Second International Colloquium on Cardio-Oncology, Krakow, May 3 - 4, 2018
Chemotherapy 2018;63:111 –111 (Source: Chemotherapy)
Source: Chemotherapy - April 26, 2018 Category: Cancer & Oncology Source Type: research

Sustained Erythroid Response in a Patient with Myelofibrosis Receiving Concomitant Treatment with Ruxolitinib and Deferasirox
Iron overload (IOL) due to transfusion-dependent anemia is a serious adverse effect in patients with myelofibrosis (MF). Recent studies have shown that the oral iron chelator deferasirox may prevent multiple organ damage due to IOL in MF. However, it is not clear whether deferasirox may contribute to revert transfusion-dependent anemia. Here, we present a patient with transfusion-dependent intermediate-2 MF according to the International Prognostic Scoring System treated with ruxolitinib in combination with deferasirox. In addition to a reduced serum ferritin level, the patient required less blood transfusions, ultimately ...
Source: Chemotherapy - April 25, 2018 Category: Cancer & Oncology Source Type: research

Identification of Risk Factors in High-Dose Methotrexate-Induced Acute Kidney Injury in Childhood Acute Lymphoblastic Leukemia
Conclusion: Increasing age, higher MTX dose per BSA, lower baseline serum protein, and first HDMTX course were significant risk factors for developing HDMTX-induced AKI in childhood ALL. The threshold of 48-h MTX plasma concentration is valuable for the prediction of HDMTX-induced AKI.Chemotherapy 2018;63:101 –107 (Source: Chemotherapy)
Source: Chemotherapy - April 19, 2018 Category: Cancer & Oncology Source Type: research

In vitro Antichlamydial Activity of 1,2,3,5-Tetrasubstituted Pyrrole Derivatives
Conclusion: Our findings highlight the potential of 1,2,3,5-tetrasubstituted pyrrole derivatives as promising lead molecules for the development of antichlamydial agents.Chemotherapy 2018;63:96 –100 (Source: Chemotherapy)
Source: Chemotherapy - April 12, 2018 Category: Cancer & Oncology Source Type: research

Erratum
Chemotherapy 2018;63:64 –64 (Source: Chemotherapy)
Source: Chemotherapy - April 10, 2018 Category: Cancer & Oncology Source Type: research

A Complete Pathological Response to Pembrolizumab following ex vivo Liver Resection in a Patient with Colorectal Liver Metastases
Advances in the systemic treatment of stage IV colorectal cancer with liver metastases has offered improved survival rates for patients who otherwise face a dismal prognosis. However, a pathologically complete response (PCR) to chemotherapy for colorectal liver metastases is still rare, and its significance is not fully understood. In this case report, we describe a patient who achieved PCR after neoadjuvant immunotherapy with pembrolizumab and a left hepatectomy using an ex vivo resection technique.Chemotherapy 2018;63:90 –94 (Source: Chemotherapy)
Source: Chemotherapy - April 5, 2018 Category: Cancer & Oncology Source Type: research

Efficacy of a Propolis-Based Syrup (FARINGEL) in Preventing Radiation-Induced Esophagitis in Locally Advanced Lung Cancer
Conclusion: FARINGEL was well-tolerated and delayed esophagitis that was induced by CRT for locally advanced lung cancer.Chemotherapy 2018;63:76 –82 (Source: Chemotherapy)
Source: Chemotherapy - March 19, 2018 Category: Cancer & Oncology Source Type: research

Radiotherapy and Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitors in Renal Cancer
This article reviews the literature behind the preclinical and clinical data of the combination of RT with VEGFR-TKIs currently approved for RCC (sunitinib, sorafenib, pazopanib, and axitinib), with a focus on dose schedules as well as efficacy and toxicity.Chemotherapy 2018;63:83 –89 (Source: Chemotherapy)
Source: Chemotherapy - March 19, 2018 Category: Cancer & Oncology Source Type: research

Beneficial and Detrimental Effects of Antiretroviral Therapy on HIV-Associated Immunosenescence
Since the introduction of highly active antiretroviral therapy more than 2 decades ago, HIV-related deaths have dramatically decreased and HIV infection has become a chronic disease. Due to the inability of antiretroviral drugs to eradicate the virus, treatment of HIV infection requires a systemic lifelong therapy. However, even when successfully treated, HIV patients still show increased incidence of age-associated co-morbidities compared with uninfected individuals. Virus- induced immunosenescence, a process characterized by a progressive decline of immune system function, contributes to the premature ageing observed in ...
Source: Chemotherapy - March 13, 2018 Category: Cancer & Oncology Source Type: research

Editorial: The Journal < b > < i > Chemotherapy < /i > < /b > Is for Cardio-Oncologists Too
Chemotherapy 2018;63:53 –54 (Source: Chemotherapy)
Source: Chemotherapy - February 9, 2018 Category: Cancer & Oncology Source Type: research

Early Diastolic Dysfunction after Cancer Chemotherapy: Primary Endpoint Results of a Multicenter Cardio-Oncology Study
Asymptomatic diastolic dysfunction (DD) with preserved left ventricular ejection fraction (LVEF) is suspected to precede late cardiac events in cancer survivors treated by chemotherapy. We conducted the first multicenter study of early DD induced by chemotherapy. Patients who were candidates for standard dose chemotherapy were screened for the absence of cardiovascular risk factors, LVEF ≥50%, normal-for-age diastolic function at echocardiography (E/A ratio, E wave deceleration time; DT), normal levels of potential DD biomarkers like Nt-proBNP (≤125 pg/mL), and cardiac troponin I (cTnI, ≤0.05 ng/mL). Mitral Dopple...
Source: Chemotherapy - February 9, 2018 Category: Cancer & Oncology Source Type: research

Antitumor Efficacy of Combination Therapy Consisting of S-1, Leucovorin, and Oxaliplatin against Human Gastric Cancer Xenografts
This study examined the antitumor efficacy of combination therapy consisting of S-1, LV, and oxaliplatin against 4 human gastric cancer xenografts: NUGC-4, St-40, SC-2, and SC-4.Methods: The antitumor efficacy was evaluated using human gastric cancer xenograft-bearing nude mice. S-1 and LV were administered orally once daily on days 1-7 at doses of 6.9 and 10 mg/kg, respectively. Oxaliplatin was administered intravenously at a dose of 8.3 mg/kg on day 1. The tumor volume was measured on day 15, and the relative tumor volume (RTV) was calculated.Results: In all 4 xenograft models, S-1 alone and oxaliplatin alone, but not LV...
Source: Chemotherapy - January 23, 2018 Category: Cancer & Oncology Source Type: research

Pazopanib-Induced Hepatotoxicity in an Experimental Rat Model
This study is the first that reports the biochemical and histopathological evaluation of pazopanib-related hepatic toxicity.Chemotherapy 2018;63:39-45 (Source: Chemotherapy)
Source: Chemotherapy - January 23, 2018 Category: Cancer & Oncology Source Type: research

Modified Colistin Regimen for Critically Ill Patients with Acute Renal Impairment and Continuous Renal Replacement Therapy
We report on the potential value of a modified regimen that adopts a loading dose of CMS (bolus of 9 MU vs. conventional 3 MU every 8 h), followed by maintenance (3 MU every 8 h). Preliminary pharmacokinetic evidence for the feasibility and efficacy of this regimen is described for 2 patients.Chemotherapy 2018;63:35-38 (Source: Chemotherapy)
Source: Chemotherapy - December 21, 2017 Category: Cancer & Oncology Source Type: research

Optimal Trough Concentration of Teicoplanin in Febrile Neutropenic Patients with Hematological Malignancy
Conclusions: The authors propose a target teicoplanin Cmin of ≥15.2 mg/L for FN in patients with hematological malignancy.Chemotherapy 2018;63:29-34 (Source: Chemotherapy)
Source: Chemotherapy - November 23, 2017 Category: Cancer & Oncology Source Type: research

Antimicrobial Activity of Galangin and Its Effects on Murein Hydrolases of Vancomycin-Intermediate Staphylococcus aureus (VISA) Strain Mu50
This study aimed to investigate the antimicrobial activity of galangin againstS. aureus and its effects on the murein hydrolases of VISA strain Mu50. This is the first report on these effects of galangin, and it may help to improve the treatment for VISA infections by demonstrating the effective use of galangin.Methods: Firstly, the minimum inhibitory concentration (MIC) and growth curve were used to investigate the antimicrobial activity of galangin againstS. aureus. Secondly, transmission electron microscopy (TEM) was used to observe morphological changes of VISA strain Mu50. Thirdly, Triton X-100-induced autolysis and c...
Source: Chemotherapy - November 17, 2017 Category: Cancer & Oncology Source Type: research

Antimicrobial Activity of Galangin and Its Effects on Murein Hydrolases of Vancomycin-Intermediate < b > < i > Staphylococcus aureus < /i > < /b > (VISA) Strain Mu50
This study aimed to investigate the antimicrobial activity of galangin againstS. aureus and its effects on the murein hydrolases of VISA strain Mu50. This is the first report on these effects of galangin, and it may help to improve the treatment for VISA infections by demonstrating the effective use of galangin.Methods: Firstly, the minimum inhibitory concentration (MIC) and growth curve were used to investigate the antimicrobial activity of galangin againstS. aureus. Secondly, transmission electron microscopy (TEM) was used to observe morphological changes of VISA strain Mu50. Thirdly, Triton X-100-induced autolysis and c...
Source: Chemotherapy - November 16, 2017 Category: Cancer & Oncology Source Type: research

Considerations about the Use of a Loading Dose of Daptomycin in a Neutropenic Murine Thigh Infection Model with Methicillin-Resistant < b > < i > Staphylococcus aureus < /i > < /b > Infection
Previous clinical studies have showed the clinical benefits of the initiation of treatment with a daptomycin (DAP) loading dose, but only a few studies have evaluated its antimicrobial benefits. We evaluated the efficacy of a DAP loading dose against methicillin-resistantStaphylococcus aureus (MRSA) infections in a neutropenic murine thigh infection model. Three MRSA isolates (DAP MIC: 0.5, 1, and 2 mg/L) were tested. Four DAP regimens simulating human concentration-time profiles, i.e., (i) day 1: 8 mg/kg and day 2: 6 mg/kg, (ii) days 1 and 2: 6 mg/kg/day, (iii) day 1: 8 mg/kg and day 2: 4 mg/kg, and (iv) days 1 and 2: 4 m...
Source: Chemotherapy - November 10, 2017 Category: Cancer & Oncology Source Type: research

Acknowledgement to Reviewers
Chemotherapy 2017;62:381 (Source: Chemotherapy)
Source: Chemotherapy - November 2, 2017 Category: Cancer & Oncology Source Type: research

Contents Vol. 62, 2017
Chemotherapy 2017;62:I-VI (Source: Chemotherapy)
Source: Chemotherapy - November 2, 2017 Category: Cancer & Oncology Source Type: research

Effect of a Shortened Duration of FOLFOX Chemotherapy on the Survival Rate of Patients with Stage II and III Colon Cancer
Conclusions: Five-year overall and disease-free survival were not significantly different between the 2 groups. Large-scale prospective studies are necessary for the analysis of complications and survival rates.Chemotherapy 2018;63:8-12 (Source: Chemotherapy)
Source: Chemotherapy - November 1, 2017 Category: Cancer & Oncology Source Type: research

High-Sensitivity Troponin T and NT-proBNP Kinetics in Breast Cancer Chemotherapy
Background/Aims: Doxorubicin (DOX) and trastuzumab (TRA) are associated with cardiac dysfunction.Method: High-sensitivity troponin T (hs-TnT) and brain natriuretic peptide attached to the amino acid N-terminal fragment in the prohormone (NT-proBNP) were measured before and on days +1, +2, +3, and +7 during cycles 1 and 2 of therapy with DOX or TRA in breast cancer patients.Results: Five of eleven DOX-treated women, compared with 2/11 TRA-treated women, had undetectable baseline hs-TnT. By day +1 of cycle 2, all the DOX-treated women (p = 0.03) but only 7/11 TRA-treated women (p = ns) had detectible hs-TnT. Time to peak was...
Source: Chemotherapy - October 25, 2017 Category: Cancer & Oncology Source Type: research

Clinical Manifestations and Prognostic Factors of Pneumocystis jirovecii Pneumonia without HIV
Conclusion: We suggest that poor PS is an independent risk factor in non-HIV PCP, and a patient's PS and disease activity may correlate with outcome.Chemotherapy 2017;62:343-349 (Source: Chemotherapy)
Source: Chemotherapy - October 25, 2017 Category: Cancer & Oncology Source Type: research

Colistin Resistance in KPC-2- and SHV-5-Producing Klebsiella pneumoniae Clinical Isolates in Bulgaria
Conclusions: Although colistin use in Bulgaria only started moderately during 2014, the findings of the current study notify the appearance of colistin resistance among carbapenemase-producingKlebsiella species in another European region.Chemotherapy 2017;62:339-342 (Source: Chemotherapy)
Source: Chemotherapy - October 25, 2017 Category: Cancer & Oncology Source Type: research

Disappearance of Bone Marrow Fibrosis in a Patient with Chronic Myeloid Leukemia Treated with Dasatinib
We report a case of a chronic myeloid leukemia patient showing progressive bone marrow fibrosis and anemia during imatinib therapy. Given the loss of major molecular response, we switched treatment to dasatinib 100 mg daily, observing a reduction in BCR-ABL transcript, a significant improvement of anemia, and a gradual disappearance of fibrosis. After 7 years of dasatinib therapy the patient maintains a complete cytogenetic response and a deep molecular response; the last bone biopsy confirmed the absence of fibrosis.Chemotherapy 2017;62:350-352 (Source: Chemotherapy)
Source: Chemotherapy - October 25, 2017 Category: Cancer & Oncology Source Type: research

Ponatinib-Induced Graft-versus-Host Disease/Graft-versus-Leukemia Effect in a Patient with Philadelphia-Positive Acute Lymphoblastic Leukemia without the T315I Mutation Relapsing after Allogeneic Transplant
We describe the case of a patient with Philadelphia-positive acute lymphoblastic leukemia treated with dasatinib plus steroids as first-line therapy, who achieved a major molecular response (MMR) before undergoing matched, unrelated donor allogeneic stem cell transplant. Eleven months after the transplant, she experienced molecular relapse. Mutational screening showed negativity for the T315I mutation, The patient underwent a salvage chemotherapy regimen with clofarabine + cyclophosphamide + steroids and ponatinib (clofarabine 70 mg i.v., days 1-5, cyclophosphamide 700 mg i.v., days 1-5, and ponatinib 45 mg p.o., daily sta...
Source: Chemotherapy - October 25, 2017 Category: Cancer & Oncology Source Type: research

The Effect of Tegafur-Uracil on Survival in T Categories as Defined in the Eighth Edition of the TNM Classification: An Exploratory Analysis of Postoperative Adjuvant Tegafur-Uracil on Survival in Patients with Adenocarcinoma of the Lung
Background: Tegafur-uracil (UFT) improves survival in patients with stage I adenocarcinoma of the lung. We evaluated the effect of UFT on survival in maximum primary tumor diameter (T) categories as defined in the eighth edition of the TNM Classification (TNM8).Methods: Tumors were subgrouped on the basis of T category (TNM8) as follows: T1a, T ≤1 cm; T1b, 1 (Source: Chemotherapy)
Source: Chemotherapy - October 25, 2017 Category: Cancer & Oncology Source Type: research

Combination Therapy with Capecitabine and Cisplatin as Second-Line Chemotherapy for Advanced Biliary Tract Cancer
Conclusions: Combination therapy with capecitabine and cisplatin may be an option for second-line chemotherapy in some of patients with advanced BTC.Chemotherapy 2017;62:361-366 (Source: Chemotherapy)
Source: Chemotherapy - October 25, 2017 Category: Cancer & Oncology Source Type: research

Severe Drug-Induced Liver Injury as an Adverse Drug Event of Antibiotics: A Case Report and Review of the Literature
We report the case of a young patient who experienced a drug-induced liver injury resulting in life-threatening acute liver failure after treatment with different antibiotics (amoxicillin, ciprofloxacin, cefazolin, clindamycin) and acetaminophen, or a combination of these drugs. Moreover, we provide an overview of the hepatotoxic potential of these drugs.Chemotherapy 2017;62:367-373 (Source: Chemotherapy)
Source: Chemotherapy - October 25, 2017 Category: Cancer & Oncology Source Type: research

Effectiveness of Nivolumab versus Docetaxel as Second-Line Treatment in Non-Small Cell Lung Cancer Patients in Clinical Practice
Conclusion: NSCLC patients treated with nivolumab as second-line therapy had a longer PFS compared to patients treated with docetaxel in a health care environment.Chemotherapy 2017;62:374-380 (Source: Chemotherapy)
Source: Chemotherapy - October 25, 2017 Category: Cancer & Oncology Source Type: research

α-Pinene Inhibits Human Prostate Cancer Growth in a Mouse Xenograft Model
Conclusions: These data strongly suggest that α-pinene inhibits prostate cancer growth in a xenograft model and may be an effective therapeutic agent for prostate cancer treatment.Chemotherapy 2018;63:1-7 (Source: Chemotherapy)
Source: Chemotherapy - October 25, 2017 Category: Cancer & Oncology Source Type: research

Effectiveness of Nivolumab versus Docetaxel as Second-Line Treatment in Non-Small Cell Lung Cancer Patients in Clinical Practice
Conclusion: NSCLC patients treated with nivolumab as second-line therapy had a longer PFS compared to patients treated with docetaxel in a health care environment.Chemotherapy 2017;62:374-380 (Source: Chemotherapy)
Source: Chemotherapy - October 18, 2017 Category: Cancer & Oncology Source Type: research

Severe Drug-Induced Liver Injury as an Adverse Drug Event of Antibiotics: A Case Report and Review of the Literature
We report the case of a young patient who experienced a drug-induced liver injury resulting in life-threatening acute liver failure after treatment with different antibiotics (amoxicillin, ciprofloxacin, cefazolin, clindamycin) and acetaminophen, or a combination of these drugs. Moreover, we provide an overview of the hepatotoxic potential of these drugs.Chemotherapy 2017;62:367-373 (Source: Chemotherapy)
Source: Chemotherapy - September 21, 2017 Category: Cancer & Oncology Source Type: research

Combination Therapy with Capecitabine and Cisplatin as Second-Line Chemotherapy for Advanced Biliary Tract Cancer
Conclusions: Combination therapy with capecitabine and cisplatin may be an option for second-line chemotherapy in some of patients with advanced BTC.Chemotherapy 2017;62:361-366 (Source: Chemotherapy)
Source: Chemotherapy - August 25, 2017 Category: Cancer & Oncology Source Type: research

The Effect of Tegafur-Uracil on Survival in T Categories as Defined in the Eighth Edition of the TNM Classification: An Exploratory Analysis of Postoperative Adjuvant Tegafur-Uracil on Survival in Patients with Adenocarcinoma of the Lung
Background: Tegafur-uracil (UFT) improves survival in patients with stage I adenocarcinoma of the lung. We evaluated the effect of UFT on survival in maximum primary tumor diameter (T) categories as defined in the eighth edition of the TNM Classification (TNM8).Methods: Tumors were subgrouped on the basis of T category (TNM8) as follows: T1a, T ≤1 cm; T1b, 1 (Source: Chemotherapy)
Source: Chemotherapy - August 17, 2017 Category: Cancer & Oncology Source Type: research

Ponatinib-Induced Graft-versus-Host Disease/Graft-versus-Leukemia Effect in a Patient with Philadelphia-Positive Acute Lymphoblastic Leukemia without the T315I Mutation Relapsing after Allogeneic Transplant
We describe the case of a patient with Philadelphia-positive acute lymphoblastic leukemia treated with dasatinib plus steroids as first-line therapy, who achieved a major molecular response (MMR) before undergoing matched, unrelated donor allogeneic stem cell transplant. Eleven months after the transplant, she experienced molecular relapse. Mutational screening showed negativity for the T315I mutation, The patient underwent a salvage chemotherapy regimen with clofarabine + cyclophosphamide + steroids and ponatinib (clofarabine 70 mg i.v., days 1-5, cyclophosphamide 700 mg i.v., days 1-5, and ponatinib 45 mg p.o., daily sta...
Source: Chemotherapy - August 15, 2017 Category: Cancer & Oncology Source Type: research

Disappearance of Bone Marrow Fibrosis in a Patient with Chronic Myeloid Leukemia Treated with Dasatinib
We report a case of a chronic myeloid leukemia patient showing progressive bone marrow fibrosis and anemia during imatinib therapy. Given the loss of major molecular response, we switched treatment to dasatinib 100 mg daily, observing a reduction in BCR-ABL transcript, a significant improvement of anemia, and a gradual disappearance of fibrosis. After 7 years of dasatinib therapy the patient maintains a complete cytogenetic response and a deep molecular response; the last bone biopsy confirmed the absence of fibrosis.Chemotherapy 2017;62:350-352 (Source: Chemotherapy)
Source: Chemotherapy - July 25, 2017 Category: Cancer & Oncology Source Type: research

Colistin Resistance in KPC-2- and SHV-5-Producing Klebsiella pneumoniae Clinical Isolates in Bulgaria
Conclusions: Although colistin use in Bulgaria only started moderately during 2014, the findings of the current study notify the appearance of colistin resistance among carbapenemase-producingKlebsiella species in another European region.Chemotherapy 2017;62:339-342 (Source: Chemotherapy)
Source: Chemotherapy - July 24, 2017 Category: Cancer & Oncology Source Type: research

Colistin Resistance in KPC-2- and SHV-5-Producing < b > < i > Klebsiella pneumoniae < /i > < /b > Clinical Isolates in Bulgaria
Conclusions: Although colistin use in Bulgaria only started moderately during 2014, the findings of the current study notify the appearance of colistin resistance among carbapenemase-producingKlebsiella species in another European region.Chemotherapy 2017;62:339-342 (Source: Chemotherapy)
Source: Chemotherapy - July 21, 2017 Category: Cancer & Oncology Source Type: research

Clinical Manifestations and Prognostic Factors of Pneumocystis jirovecii Pneumonia without HIV
Conclusion: We suggest that poor PS is an independent risk factor in non-HIV PCP, and a patient's PS and disease activity may correlate with outcome.Chemotherapy 2017;62:343-349 (Source: Chemotherapy)
Source: Chemotherapy - July 18, 2017 Category: Cancer & Oncology Source Type: research

Clinical Manifestations and Prognostic Factors of < b > < i > Pneumocystis jirovecii < /i > < /b > Pneumonia without HIV
Conclusion: We suggest that poor PS is an independent risk factor in non-HIV PCP, and a patient's PS and disease activity may correlate with outcome.Chemotherapy 2017;62:343-349 (Source: Chemotherapy)
Source: Chemotherapy - July 18, 2017 Category: Cancer & Oncology Source Type: research

High-Sensitivity Troponin T and NT-proBNP Kinetics in Breast Cancer Chemotherapy
Background/Aims: Doxorubicin (DOX) and trastuzumab (TRA) are associated with cardiac dysfunction.Method: High-sensitivity troponin T (hs-TnT) and brain natriuretic peptide attached to the amino acid N-terminal fragment in the prohormone (NT-proBNP) were measured before and on days +1, +2, +3, and +7 during cycles 1 and 2 of therapy with DOX or TRA in breast cancer patients.Results: Five of eleven DOX-treated women, compared with 2/11 TRA-treated women, had undetectable baseline hs-TnT. By day +1 of cycle 2, all the DOX-treated women (p = 0.03) but only 7/11 TRA-treated women (p = ns) had detectible hs-TnT. Time to peak was...
Source: Chemotherapy - July 13, 2017 Category: Cancer & Oncology Source Type: research